☰

Syvento Therapeutics Sp. z o.o.

Scaling mRNA therapeutics production

A biotech scaling its LNP-mRNA platform from microlitres to 50 litres with digital infrastructure and a CDMO portal

Industry
Biotechnology (mRNA and LNP Therapeutics)
Headquarters
Warsaw, Poland
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Syvento Therapeutics Sp. z o.o.'s published strategy and is not endorsed by, or produced in cooperation with, Syvento Therapeutics Sp. z o.o.. Company website

Strategic priorities

Syvento Therapeutics Sp. z o.o. is a Warsaw-based biotech company and CDMO specialising in lipid nanoparticle and mRNA therapeutics. The company is executing a high-stakes transition from specialised R&D startup to commercially ready mRNA manufacturing leader, backed by EUR 100-150M from MS Galleon Group. The immediate priority is establishing Poland as a self-sufficient pharmaceutical manufacturing hub while scaling from 25 µl lab processes to 50 L commercial batches — a 2-million-fold scale jump that requires systematic digital infrastructure, not just bigger tanks. Key strategic initiatives include using the first-in-Poland MIA certification to capture CDMO market share, deploying advanced fill-finish capabilities at 2,000-3,000 vials per hour, and building digital infrastructure that enables transparent partnerships with global pharmaceutical clients.

The defining challenge is the scale-up data gap. A 2-million-fold scale jump from 25 µl to 50 L creates physics that are not linear — heat transfer, mixing dynamics and oxygen transfer behave differently at industrial scale. Without systematic scale-up models and real-time monitoring, the first sign of a scale-up problem is a failed batch rather than an early warning from data. Beyond the technical scale-up challenge, the company must build CDMO customer engagement infrastructure — pharmaceutical clients expect real-time visibility into manufacturing progress, quality data and batch documentation, delivered through a digital portal rather than email exchanges.

On the compliance side, pharmaceutical manufacturing requires systematic ALCOA+ and GxP documentation that grows with production volume. Manual compliance processes cannot scale to 50 L commercial batch volumes without creating bottlenecks that delay batch release.

Challenges we see

  • Operations Bioprocess

    Scale-up data gap creating batch failure risk at 50 L commercial scale

    A 2-million-fold scale jump from 25 µl lab processes to 50 L commercial batches creates non-linear physics — heat transfer, mixing dynamics, oxygen transfer — that cannot be managed with the trial-and-error approach that worked at laboratory scale. Without scale-up models and real-time monitoring, failed batches during commercial scale-up could delay MIA certification milestones.

    Where scale-up relies on trial and error, the first sign of a scale-up problem is a failed batch. A digital scale-up platform means the commercial operating envelope is characterised in simulation before the first 50 L batch runs.

  • Digital Integration

    Fragmented industrial data preventing cross-functional analytics

    Syvento's data is spread across disconnected systems — LIMS, ERP, MES, batch records — that do not communicate. Cross-functional analytics that could improve process yields and reduce deviations require manual data reconciliation before analysis can begin.

    Where data is fragmented by system, the insights that would improve yields are invisible until someone looks for them. A unified data platform means the full dataset is available for analysis without manual reconciliation.

  • Compliance Regulatory

    Manual compliance documentation creating batch release bottlenecks

    Pharmaceutical manufacturing requires systematic GxP documentation for every batch. As production scales from laboratory to 50 L commercial volumes, manual compliance processes create bottlenecks that delay batch release and consume quality team capacity.

    Where compliance documentation is manual, the batch release timeline is set by documentation speed rather than by quality testing completion. Automated compliance means the documentation is generated as the batch runs.

  • Digital Manufacturing

    No smart component integration for real-time bioprocess monitoring

    Critical bioprocess parameters — lipid composition, pH, temperature — are monitored with sensors that provide data but do not enable real-time closed-loop control. The absence of smart component integration means process adjustments are made retrospectively rather than in real time.

    Where process monitoring is passive, the process runs open-loop. Smart component integration with real-time monitoring means deviations are corrected automatically before they affect product quality.

  • Commercial Operations

    No CDMO customer portal creating engagement gaps with pharmaceutical clients

    Pharmaceutical CDMO clients expect real-time visibility into manufacturing progress, quality data and batch documentation. Syvento currently manages client communication through email and document exchanges, creating engagement gaps and slowing client approval processes.

    Where client engagement is email-based, the client's visibility into their project status is limited to what is proactively communicated. A CDMO portal means the client has real-time visibility without needing to ask.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Digital scale-up platform for Syvento LNP-mRNA manufacturing

    A 2-million-fold scale jump from 25 µl to 50 L creates non-linear physics that cannot be managed with trial-and-error. Without scale-up models, failed batches during commercial scale-up could delay MIA certification milestones and client delivery commitments.

    Deploy a digital scale-up platform that combines process modelling, historical data analysis and real-time monitoring to characterise the 50 L operating envelope before full-scale production begins.

    • Syvento scale-up assessment, 2025

  2. Unified industrial data platform for Syvento cross-functional analytics

    Data is fragmented across LIMS, ERP, MES and batch records without integration. Cross-functional analytics require manual data reconciliation, delaying the process optimisation insights that could improve yields.

    Build a unified industrial data platform that integrates all Syvento data systems, enabling cross-functional analytics that surface process improvement opportunities without manual data preparation.

    • Syvento data infrastructure assessment, 2025

  3. Automated compliance documentation for pharmaceutical batch release

    Manual GxP documentation cannot scale to 50 L commercial batch volumes without creating batch release bottlenecks. Quality team capacity is consumed by documentation rather than by value-added quality oversight.

    Implement automated compliance documentation that generates GxP batch records as manufacturing progresses, eliminating the documentation bottleneck and accelerating batch release timelines.

    • Syvento quality operations assessment, 2025

  4. Smart bioprocess component integration for real-time closed-loop control

    Critical process parameters are monitored passively without real-time control capability. Process deviations are corrected retrospectively rather than prevented in real time, creating quality risk for mRNA/LNP products with narrow therapeutic windows.

    Integrate smart bioprocess components with real-time monitoring and closed-loop control, enabling automatic process adjustments that maintain product quality within specification in real time.

    • Syvento bioprocess capability assessment, 2025

  5. CDMO customer portal for pharmaceutical client engagement

    Pharmaceutical CDMO clients expect real-time visibility into project status, quality data and batch documentation. Email-based communication creates engagement gaps and slows the approval processes that CDMO projects depend on.

    Build a CDMO customer portal that gives pharmaceutical clients real-time visibility into manufacturing progress, quality documentation and batch records, differentiating Syvento from CDMO competitors that rely on email communication.

    • Syvento commercial capability assessment, 2025

What we'd propose

  • Digital CDMO

    Digital scale-up platform for Syvento LNP-mRNA commercial manufacturing

    We design and deploy a digital scale-up platform for Syvento that combines bioprocess modelling, historical data analysis and real-time monitoring to characterise the 50 L commercial operating envelope, reducing scale-up batch failure risk and accelerating MIA certification for commercial manufacturing.

    • Bioprocess scale-up model development

      Scale-up physics captured in a validated process model

      Build bioprocess scale-up models that capture the non-linear physics — heat transfer, mixing dynamics, oxygen transfer — of scaling from 25 µl to 50 L, characterising the commercial operating envelope before full-scale production begins.

    • Real-time scale-up monitoring dashboard

      Scale-up parameters tracked in real time against predicted values

      Deploy a real-time scale-up monitoring dashboard that tracks critical process parameters during scale-up campaigns against the predicted values from the scale-up model, alerting operators when actual values deviate from predictions.

    • Scale-up knowledge base for future LNP-mRNA products

      Scale-up methodology reusable across the product pipeline

      Build a scale-up knowledge base that captures the methodology, parameters and lessons learned from the 25 µl to 50 L scale-up, providing a reusable framework for future LNP-mRNA product introductions.

    • Scale-up batch failure risk reduced by characterising the operating envelope before commercial batches run.
    • MIA certification timeline protected by demonstrating systematic scale-up methodology to regulators.
    • Future product scale-up accelerated by the knowledge base established from the first scale-up campaign.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Unified industrial data platform for Syvento cross-functional operations

    We build a unified industrial data platform for Syvento that integrates LIMS, ERP, MES and batch record data into a single analytical environment, enabling cross-functional analytics that improve process yields and reduce deviations across the mRNA-LNP manufacturing operation.

    • LIMS-ERP-MES batch record data integration

      All data systems connected to one analytical platform

      Build data integration pipelines from LIMS, ERP, MES and batch record systems into a unified data warehouse, eliminating the manual data reconciliation that currently precedes every cross-functional analysis.

    • Process yield analytics and deviation pattern detection

      Yield improvement opportunities identified from integrated data

      Develop process yield analytics that combine data from all systems to identify the process parameter combinations that produce the highest yields and the deviation patterns that most frequently lead to quality events.

    • Real-time operational visibility dashboard

      Cross-functional operations visible in real time

      Deliver a real-time operational visibility dashboard that gives Syvento management and operations teams live insight into production status, quality metrics and inventory positions across all systems without requiring multiple logins.

    • Process yield improvement opportunities identified by analytics that manual data reconciliation previously prevented.
    • Quality event root cause analysis accelerated by having all relevant data in one platform.
    • Operations decision-making improved by real-time visibility rather than periodic report review.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Automated compliance documentation for Syvento pharmaceutical batch release

    We implement automated compliance documentation for Syvento that generates GxP batch records as manufacturing progresses, eliminating the documentation bottleneck that manual processes create at commercial batch volumes and accelerating batch release timelines.

    • Automated batch record generation from MES data

      Batch records assembled automatically as manufacturing progresses

      Build automated batch record generation that captures critical process parameters, material inputs and quality test results from the MES as manufacturing progresses, assembling the batch record without manual data entry.

    • ALCOA+ compliant data capture infrastructure

      Data integrity requirements built into the data capture layer

      Implement ALCOA+ compliant data capture infrastructure that ensures all batch record data is attributable, legible, contemporaneous, original and accurate from the point of generation, satisfying regulatory requirements at the data capture layer.

    • Batch release accelerated documentation workflow

      Quality review conducted on complete digital batch records

      Build a batch release workflow that presents quality reviewers with complete digital batch records that are assembled automatically as manufacturing completes, reducing the batch release timeline from days to hours.

    • Batch release timeline reduced from days to hours by eliminating the manual documentation bottleneck.
    • Quality team capacity redirected from documentation assembly to value-added quality oversight.
    • Regulatory inspection readiness improved by compliance documentation that is complete and accurate.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Smart bioprocess component integration for Syvento real-time process control

    We integrate smart bioprocess components for Syvento's LNP-mRNA manufacturing process with real-time monitoring and closed-loop control capability, enabling automatic process adjustments that maintain product quality within specification in real time.

    • Real-time process parameter monitoring with smart sensors

      Critical parameters monitored and controlled in real time

      Deploy smart sensors for critical bioprocess parameters — lipid composition, pH, dissolved oxygen, temperature — that provide real-time data and closed-loop control capability rather than passive monitoring.

    • Closed-loop automated process adjustment

      Process deviations corrected automatically within specification

      Build closed-loop automated process adjustment that uses real-time sensor data to make automatic parameter adjustments — flow rates, temperature setpoints, pH control — within validated operating ranges.

    • Smart component integration with MES

      Smart components connected to MES for complete process visibility

      Integrate smart bioprocess components with the Syvento MES, ensuring that real-time control actions and process data are visible to operators and quality teams in the same system.

    • Product quality risk reduced by automatic real-time process adjustments that prevent deviations from becoming quality events.
    • Operator workload reduced by closed-loop control that handles routine parameter adjustments automatically.
    • Scale-up risk reduced by process control that is more precise at commercial scale than manual operation allows.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    CDMO customer portal for Syvento pharmaceutical client engagement

    We build a CDMO customer portal for Syvento that gives pharmaceutical clients real-time visibility into manufacturing progress, quality documentation and batch records, differentiating Syvento from CDMO competitors that rely on email-based client communication.

    • Real-time project status visibility

      Clients see their project status updated continuously

      Build a client-facing portal that gives pharmaceutical CDMO customers real-time visibility into manufacturing campaign status, sample shipment tracking and quality documentation availability, eliminating the status email exchanges that currently create communication gaps.

    • Quality document sharing and approval workflow

      Clients review and approve documents through the portal

      Implement quality document sharing and approval workflows that deliver batch records, certificate of analysis and other quality documents to clients through the portal, with digital approval signatures and full audit trails.

    • Client-specific data environment with data room security

      Each client's data isolated in a secure, compliant environment

      Deploy client-specific data environments that isolate each pharmaceutical customer's data within a secure, compliant data architecture, enabling transparent partnership without compromising data security or regulatory compliance.

    • Customer relationship differentiation created by real-time portal access that CDMO competitors using email cannot match.
    • Client approval cycle time reduced by digital approval workflows that replace email-based document exchanges.
    • New business development supported by the portal being a demonstrable capability in sales conversations.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Syvento Therapeutics Sp. z o.o.'s own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Scale-Up Data Infrastructure 15 → 80
No systematic scale-up platform exists. The 25 µl to 50 L scale-up relies on trial-and-error rather than modelling and simulation. No digital twin of the scale-up process is deployed.
Industrial Data Integration 20 → 80
Data is fragmented across LIMS, ERP, MES and batch records without integration. No unified data platform exists. Cross-functional analytics require manual data reconciliation.
Compliance Automation 20 → 80
GxP batch record documentation is manual. No automated compliance documentation system is deployed. Batch release is delayed by documentation completion speed.
Smart Bioprocess Control 15 → 75
Critical process parameters are monitored passively. No smart component integration or closed-loop real-time control is deployed. Process adjustments are made retrospectively.
CDMO Customer Engagement 15 → 70
CDMO client communication is email-based. No customer portal exists. Clients have no real-time visibility into project status or quality documentation.
MIA Certification Readiness 30 → 85
MIA certification is first-in-Poland but not yet demonstrated at commercial scale. Digital compliance and scale-up infrastructure must be operational before certification inspection.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Syvento Therapeutics Sp. z o.o., and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].